Navigation Links
Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA

the BiTE molecule targeting EphA2 killed tumor cells at dose levels considerably below those required by classical monoclonal antibody-based therapies in in vivo and in vitro proof-of-concept studies.

"The EphA2 and CEA antigens are the focus of ongoing preclinical research within MedImmune's broad pipeline of potential treatments for cancer," said Peter Kiener, MedImmune's Senior Vice President, Research. "Both have been implicated in the growth and survival of a range of tumor types, and we are encouraged by the preclinical study results to date with these two highly potent BiTE molecules."

About BiTE(R) Molecules

BiTE molecules are a novel class of antibody derivatives with the potential to selectively direct and activate an individual's cytotoxic T cells, the body's most potent killer cells, to act against cancer cells. MT103/MEDI-538, a BiTE molecule targeting the B cell antigen CD19, provided clinical proof-of-concept for the BiTE platform technology, as presented at the last meeting of the American Society for Hematology. In an ongoing phase 1 study, MT103/MEDI-538 has shown potent elimination of tumor target cells in peripheral blood, bone marrow, lymph nodes and spleen of therapy-refractory non-Hodgkins lymphoma patients.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
4. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
5. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
8. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
9. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
10. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
11. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR

Post Your Comments:
(Date:11/6/2009)...ESTBURY, N.Y., Nov. 6 Repossession...ne tools in the third quarter of 2009 declined as ...o Nassau Asset Management,s NasTrac Quarterly Inde...ctivity reports for both repossessions and orderly...ons for both construction and printing equipment, ...
(Date:11/6/2009)...RINCETON, N.J., Nov. 6 ..., a provider of advanced wound care products, anno...lts before market on Monday, November 16, 2009. Th...y to discuss the results at 11:00 am EST. Interest...r (857) 350-1684 (international), with passcode 81...
(Date:11/6/2009)...URRYSVILLE, Pa., Nov. 6 Philips Re...Disease Control and Prevention (CDC) to raise awar...ronic sleep insufficiency. The CDC,s release of th...state differences in sleeplessness is a milestone ... ,, As a long-time educator, industry leader an...
Breaking Medicine Technology:NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Slimbolics Signs Marketing Contract for Its Revolutionary Weight Loss Aid 54032 1Slimbolics Signs Marketing Contract for Its Revolutionary Weight Loss Aid 54032 2Jim Deal Appointed to MedCaths Board of Directors 54027 1Jim Deal Appointed to MedCaths Board of Directors 54027 2California Cryobank Names Richard Jennings President of FamilyCord Division 4838 1California Cryobank Names Richard Jennings President of FamilyCord Division 4838 2
...ponse Rate to Combination Treatment, FRAZER, Pa.,...today that in a phase 2 study published online tod... of patients with relapsed indolent,B-cell and man... treatment,with TREANDA(R) (bendamustine hydrochlo...on study is one of three studies in patients with ...
...14 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) tod... program to evaluate MAP0004 as a potential treatm...self-administered at home using MAP,Pharmaceutical...prior Phase,2 efficacy study, MAP0004 provided pai...ained through at least 24 hours. The study also,de...
Other Medicine Technology:Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 2Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 3Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 4Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 5MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 3MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 4
(Date:11/7/2009)...k (GA), Louis J. Goodman (TX), Palmer P. Jones (NH...v. 7 The American Medic...society executive leaders with achievement awards ...ls of the medical profession. The awards were pres...ng in Houston. ,, (Logo: http://www.newscom....
(Date:11/7/2009)...-- Members of the AMA are trying a last-minute tac...g the AMA,s support of HR 3962. ,, "We want to...eir PATIENTS, not the leadership of the AMA," said...ation of American Physicians and Surgeons, and Tak...ps. ,, "If the AMA leadership ignores the publ...
(Date:11/7/2009)...onsibility to vigorously oppose abortion in health...NGTON, Nov. 7 Americ...following statement on the news that Cardinal Just...rdable Health Care for America Act (H.R. 3962), pr...abortion is voted upon. ,, "Our Catholic bisho...
(Date:11/7/2009)...e/ -- Speaker Nancy Pelosi and Democratic leaders ... a Democratic Whip meeting with President Obama in...opening remarks: ,, "Thank you very much, Mr. ...ive the President of the United States on this day...making progress for the American people. ,, "...
(Date:11/7/2009)...y of America (PRSA) will bestow the distinguished ... president of Brand Strategy, Communications and P...PRSA,s 2009 International Conference in San Diego....lows is one of the profession,s highest individual...RSA, and 2009 chair of the College of Fellows. "It...
Breaking Medicine News(10 mins):Health News:AMA Honors Medical Society Executives 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3
... COLUMBUS , Ohio The chronic stress that spouses... disease patients may shorten the caregivers, live...uggests. , The research also provides concrete e...ed this month by researchers from Ohio State Unive...
...NION CITY, Calif., Sept. 18 Abaxis, Inc.,(Nasdaq:... point-of-care,blood analysis systems, announced t...present at the 2007 UBS Global Life Science Confer... presentation at, http://www.ibb.ubs.com . Click o...
... PHILADELPHIA − Human white blood cells, en..., could provide a novel therapy for patients with ...lastic leukemia (ALL), according to researchers at...s human B cells, the researchers were able to erad...
...OUNTAIN VIEW, Calif., Sept. 18 Pharsight,Corporat... of software and,strategic services for optimizing...t has filed an application to list its common stoc...r Pharsight," said Shawn,O,Connor, president, CEO,...
...assportMD Offers Safe, Secure & Free Personal Heal...t. 18 News that radio frequency,identification (R... even,cancer -- has the healthcare and personal he...nd non-invasive alternative already exists. Consum...
...onsumers Urged To Use Online Quality Information B...spital, MINNEAPOLIS, Sept. 18 The Leapfrog Group...oday released this year,s results from a,comprehen...rens, Hospitals and Clinics in Minneapolis and St....
Other Medicine News:Health News:Chronic stress can steal years from caregivers' lifetimes 2Health News:Chronic stress can steal years from caregivers' lifetimes 3Health News:Abaxis to Present at the 2007 UBS Global Life Science Conference 2Health News:T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells 2Health News:T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells 3Health News:Pharsight Files Application for Nasdaq Capital Market Listing 2Health News:Pharsight Files Application for Nasdaq Capital Market Listing 3Health News:RFID Implant Cancer Questions Concern Patients 2Health News:Four Minnesota Hospitals Rate High For Patient Safety and Quality 2
...g; and Zyplast® injectable collagen implants h...hing facial lines, wrinkles and scars and in provi...the skins natural collagen, require minimal proced...re than one million people worldwide have been tre...
Captique™ Hyaluronic Acid Dermal Filler
...ge of non-surgical facial contouring materials. Yo... results for various applications with exceptional...fers superior versatility for a wide variety of no... Long-lasting, Radiesse saves time and money for b...
HEMOCHRON Model 401 Coagulation Monitoring Instrument
Medicine Products: